Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | EVP, WWC. Innovative Medicine | August 17, 2026 | August 18, 2026 |
| MCDONALDS CORPMCD · Entity 2849 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,451.001 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 15,000 · Balance 209,451.001 Row 2 · 2026-08-17 · Sale · Disposed 15,000 · Balance 194,451.001 F1: This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.67 · Expires 2027-02-13 | Direct | 28,712 |
Reported balance
After 2026-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-17 · Exercise / conversion · Disposed 15,000 · Balance 28,712 F2: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date.
MCDONALDS CORP
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | Direct | 4,108.7 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 129.9 · Balance 4,108.7 F1: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan"). F2: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation. F3: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board. F4: Includes shares acquired through dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of McDonald's Corporation common stock and shall be settled in cash, pursuant to the Board of Directors' Deferred Compensation Plan (the "Plan").
F2: Acquisition of phantom stock pursuant to the Plan in a transaction exempt under Rule 16b-3(d)(1). Amount represents deferred compensation.
F3: Payment of phantom stock will occur following the Director's retirement date or other termination from the Board.
F4: Includes shares acquired through dividend reinvestment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 3,951 | $150.46 | $594,467.46 |
DisclosureSEC source: 0001225208-20-002666 · doc4.xml · nonDerivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,862.001 F3 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 7,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002666 · doc4.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,813.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:03 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 8,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002666 · doc4.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,089.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 13, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:47 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002101 · doc4.xml · derivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,570 Underlying: Common Stock · 3,570 shares Expires not disclosed F3 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F3 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:47 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantPerformance Share Units · Derivative | 8,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002101 · doc4.xml · derivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,360 Underlying: Common Stock · 8,360 shares Expires not disclosed F2 · derivative.exercise_price: On February 10, 2020, the Issuer's Compensation & Benefits Committee certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 13, 2017 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date F2 · derivative.expiration_date: On February 10, 2020, the Issuer's Compensation & Benefits Committee certified the performance factor applicable to Performance Share Units awarded to the reporting person on February 13, 2017 under the Issuer's Long-Term Incentive Plan. These Performance Share Units represent a contingent right to an equal number of shares of Common Stock or the cash value thereof, subject to the reporting person's continued service to the Issuer through the third anniversary of the initial award date Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:47 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 91,324 | $0.00 Strike: $151.41 | $0.00 |
DisclosureSEC source: 0001225208-20-002101 · doc4.xml · derivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,324 Underlying: Common Stock · 91,324 shares Expires 2030-02-10 F1 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 48,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-001596 · doc4.xml · derivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 1, 2017; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 1, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 23,721 | $149.32 | $3,542,019.72 |
DisclosureSEC source: 0001225208-20-001596 · doc4.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,729.001 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:31 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 48,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-001596 · doc4.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,450.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 1, 2017; converted into shares of Common Stock upon vesting. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantRestricted Share Units · Derivative | 3,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · derivative · entry 9 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,297 Underlying: Common Stock · 3,297 shares Expires not disclosed F7 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. F7 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. Each Restricted Share Unit represents a contingent right to receive one share of Common Stock and vests three years after date of grant. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionPerformance Share Units · Derivative | 9,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · derivative · entry 8 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board. F3 · derivative.expiration_date: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantEmployee Stock Options (Right to Buy) · Derivative | 67,397 | $0.00 Strike: $131.94 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · derivative · entry 7 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,397 Underlying: Common Stock · 67,397 shares Expires 2029-02-11 F6 · security: Awarded under Issuer's Long-Term Incentive Plan. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 6,236 | $131.94 | $822,777.84 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · nonDerivative · entry 5 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,751.371 F5 · shares: Shares withheld for payment of taxes upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | GrantCommon Stock | 1,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · nonDerivative · entry 4 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,987.371 F4 · shares: Shares earned due to performance factor of 116.4% upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 9,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · nonDerivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,388.371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Performance Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting of Performance Share Units and certification of performance results by the Board. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionRestricted Share Units · Derivative | 8,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · derivative · entry 6 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,529 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Tax withholdingCommon Stock | 3,565 | $132.00 | $470,580.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,640.371 F2 · shares: Shares withheld for payment of taxes upon vesting of Restricted Share Units. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:15 UTC | JOHNSON & JOHNSON JNJ · Entity 2722 | Exercise / conversionCommon Stock | 8,529 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002353 · doc4.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WW Chair, Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,205.371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 8, 2016; converted into shares of Common Stock upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.